Compare Amylx Pharmaceuticals Inc (AMLX) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Gold Fields Limited — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Gold Fields Limited trades at $41 (market cap $36.07B). The key difference: Gold Fields Limited is far larger — about 13.7× Amylx Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 5.76% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GFI | |
|---|---|---|
Market Cap | $2.64B | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $24.19 | $61.52 |
52-Week Low | $7.82 | $29.31 |
Enterprise Value | $2.39B | $37.51B |
Dividend Yield | — | 5.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Gold Fields (GFI) trades at $41.06, down 0.16% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong fundamentals with a P/E of 10.22, net income margin of 40.76%, and robust cash flow growth, with 2025 projections indicating revenue of $8.8B and net income of $3.6B. Recent news highlights institutional buying interest, such as Assenagon Asset Management's new position in Q2 2026.
The outlook for GFI is positive, supported by high profitability and growth projections, though risks include volatile gold prices and cost pressures. Analyst consensus is a Buy with a $52 price target, suggesting 27% upside. Investors should weigh strong cash generation against debt increases and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
